1481 related articles for article (PubMed ID: 8747596)
21. Mutation and expression of TP53 in malignant melanomas.
Weiss J; Heine M; Arden KC; Körner B; Pilch H; Herbst RA; Jung EG
Recent Results Cancer Res; 1995; 139():137-54. PubMed ID: 7597286
[TBL] [Abstract][Full Text] [Related]
22. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas.
Zietz C; Rössle M; Haas C; Sendelhofert A; Hirschmann A; Stürzl M; Löhrs U
Am J Pathol; 1998 Nov; 153(5):1425-33. PubMed ID: 9811333
[TBL] [Abstract][Full Text] [Related]
23. [Immunohistochemical detection of the gene p53 and p21 expression in cells of the malignant melanoma of the uvea].
Tokosová E; Hermanová M; Uhmannová R; Smardová J; Hlinomazová Z
Cesk Slov Oftalmol; 2008 Jul; 64(4):153-6. PubMed ID: 18780655
[TBL] [Abstract][Full Text] [Related]
24. Expression of hMSH2 gene and mutant p53 in sporadic digestive tract tumors.
Kang Y; Zhang Z; Wang J; Chen J; Peng B; Kang P
Chin Med J (Engl); 2003 Jan; 116(1):53-6. PubMed ID: 12667388
[TBL] [Abstract][Full Text] [Related]
25. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
26. Analysis of the functional integrity of the p53 tumor-suppressor gene in malignant melanoma.
Knopf A; Plettenberg C; Pickhard A; Bas M; Reifenberger J; Bier H; Balz V
Melanoma Res; 2011 Oct; 21(5):380-8. PubMed ID: 21691232
[TBL] [Abstract][Full Text] [Related]
27. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type.
Akslen LA; Monstad SE; Larsen B; Straume O; Ogreid D
Int J Cancer; 1998 Feb; 79(1):91-5. PubMed ID: 9495365
[TBL] [Abstract][Full Text] [Related]
28. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas.
Patterson H; Gill S; Fisher C; Law MG; Jayatilake H; Fletcher CD; Thomas M; Grimer R; Gusterson BA; Cooper CS
Br J Cancer; 1994 Jun; 69(6):1052-8. PubMed ID: 8198970
[TBL] [Abstract][Full Text] [Related]
29. P53 and mdm-2: interactions between tumor suppressor gene and oncogene products.
Perry ME; Levine AJ
Mt Sinai J Med; 1994 Sep; 61(4):291-9. PubMed ID: 7969222
[TBL] [Abstract][Full Text] [Related]
30. Accumulation of wild type p53 protein in human astrocytomas.
Rubio MP; von Deimling A; Yandell DW; Wiestler OD; Gusella JF; Louis DN
Cancer Res; 1993 Aug; 53(15):3465-7. PubMed ID: 8339248
[TBL] [Abstract][Full Text] [Related]
31. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma.
Polsky D; Bastian BC; Hazan C; Melzer K; Pack J; Houghton A; Busam K; Cordon-Cardo C; Osman I
Cancer Res; 2001 Oct; 61(20):7642-6. PubMed ID: 11606406
[TBL] [Abstract][Full Text] [Related]
32. Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas.
Ittmann M; Wieczorek R; Heller P; Dave A; Provet J; Krolewski J
Am J Pathol; 1994 Aug; 145(2):287-93. PubMed ID: 8053489
[TBL] [Abstract][Full Text] [Related]
33. Mutation and expression of the p53 gene in human malignant melanoma.
Albino AP; Vidal MJ; McNutt NS; Shea CR; Prieto VG; Nanus DM; Palmer JM; Hayward NK
Melanoma Res; 1994 Feb; 4(1):35-45. PubMed ID: 8032216
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of MDM-2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma cell lines.
Cheng YT; Li YL; Wu JD; Long SB; Tzai TS; Tzeng CC; Lai MD
Mol Carcinog; 1995 Jul; 13(3):173-81. PubMed ID: 7619220
[TBL] [Abstract][Full Text] [Related]
35. Expression of mutant p53 in melanoma.
Stretch JR; Gatter KC; Ralfkiaer E; Lane DP; Harris AL
Cancer Res; 1991 Nov; 51(21):5976-9. PubMed ID: 1933861
[TBL] [Abstract][Full Text] [Related]
36. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
37. Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin.
Dereure O; Levi E; Vonderheid EC; Kadin ME
J Invest Dermatol; 2002 Jun; 118(6):949-56. PubMed ID: 12060388
[TBL] [Abstract][Full Text] [Related]
38. Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma.
Omholt K; Platz A; Ringborg U; Hansson J
Int J Cancer; 2001 Jun; 92(6):839-42. PubMed ID: 11351304
[TBL] [Abstract][Full Text] [Related]
39. Absence of p53 gene mutation and infrequent overexpression of p53 protein in hepatoblastoma.
Chen TC; Hsieh LL; Kuo TT
J Pathol; 1995 Jul; 176(3):243-7. PubMed ID: 7674087
[TBL] [Abstract][Full Text] [Related]
40. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
